Table 4.

Reach: pre- and post-implementation group-level depression and anxiety scores among instrument completers

	Prior to any screening implementation	Immediate pre-implementation	Post-implementation	Clinic post-implementation	Virtual post-implementation
	N = 36	N = 69	N = 275	N = 206	N = 69
Anxiety (GAD-7)	9.9 ± 6.2 [7.8,12.0]	7.2 ± 6.6 [5.7,8.8]	5.7 ± 5.6 [5.1,6.4]	5.9 ± 5.7 [5.1,6.7]	5.2 ± 5.5 [3.9,6.5]
Anxiety score severity
Normal (0-4)	28%(10)	43% (30)	49% (136)	48% (99)	54% (37)
Mild (5-9)	19%(7)	20% (14)	30% (82)	30% (61)	30% (21)
Moderate (10-14)	28%(10)	17% (12)	10% (28)	11% (23)	7.3% (5)
Severe (15-21)	25% (9)	19% (13)	11% (29)	11% (23)	8.7% (6)
Depression (NDDI-E)	14.2 ± 4.2 [12.7,15.6]	12.9 ± 5.1 [11.7,14.1]	12.0 ± 4.4 [11.5,12.6]	12.1 ± 4.4 [11.5,12.7]	11.9 ± 4.5 [10.8,13.0]
NDDI-E score>13	58%(21)	49% (34)	35% (95)	35% (73)	32% (22)
NDDI-E score>15	39%(14)	36% (25)	23% (63)	23% (48)	22% (15)
Positive passive suicidality screen (NDDI-E item 4 response 3 or 4)		12% (8)	8.7% (24)	7.8% (16)	12% (8)
Quality of Life (QOLIE-10)		68.5 ± 23.5 [58.8,78.2]	72.9 ± 20.0 [70.5,75.4]	72.8 ± 19.6 [70.1,75.5]	73.4 ± 21.4 [67.9,78.9]

Note: Mean±SD [95% Confidence Interval] or % (N); Instrument completers were defined as individuals having completed both the GAD-7 instrument and NDDI-E. Timeframes: prior to any screening implementation: March 1, 2017-May 31, 2017; immediate pre-implementation: Sept 12,2019-Dec 11, 2019; post-implementation Dec 12, 2019-May 14, 2020; clinic post-implementation Dec 12, 2019-March 24, 2020; virtual post-implementation March 25, 2020-May 14, 2020. Total N for the QOLIE-10: Immediate pre-implementation, 25; Post-implementation, 265; Clinic post-implementation, 206; Virtual post-implementation, 61. QOLIE-10 and item level responses on NDDI-E were not collected during prior to any screening implementation.